Isla D, De Las Peñas R, Insa A, et al. - Given that concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), researchers tested the effectiveness and safety of oral vinorelbine and cisplatin (OVP) vs etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting. This investigation took place in Spain, including 23 hospitals. For this open-label, randomized phase II trial, adults with untreated unresectable stage III NSCLC were randomized1:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1–5 and 29–32 with cisplatin on days 1 and 8 in 4-week cycles; 2 cycles in concomitance). The study sample consisted of 140 patients. There were 69 patients receiving OVP and 71 patients receiving EP. For the treatment of LA-NSCLC patients, OVP could be considered a standard combination with similar effectiveness and better safety profile.